Karyopharm Therapeutics Inc (NAS:KPTI)
$ 1.06 0.05 (4.9%) Market Cap: 123.45 Mil Enterprise Value: 104.37 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 76/100

Karyopharm Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2021 / 01:30PM GMT
Release Date Price: $9.26 (+1.20%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

It's my pleasure that I'd like to welcome Richard Paulson, the CEO of Karyopharm. Thanks for joining us today, Richard.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Good morning, Maury. Great to be here.

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

We're going to do a fireside chat. So maybe to start off, if you want to provide a 1-minute intro to Karyopharm, and maybe talk about some of the key catalysts at.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Sure. I think, Maury, I mean, as you know, and I think as many investors know, Karyopharm is now a fully commercial-stage organization, really founded in science and founded in development of the selective inhibition of nuclear export. And we are the leader in that with selinexor and our next-generation molecule eltanexor, with 3 approved

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot